ArticleOncoTargets and therapy2026
Design and Engineering of Recombinant Oncolytic Adenoviruses Expressing an Anti-EpCAM/Anti-CD3 BiTE for Targeted Immunotherapy of A549 Lung Cancer Cells.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oncolytic virotherapy is a novel therapeutic approach in oncology that uses viruses to target and eradicate cancer cells specifically. To improve therapeutic effectiveness, we investigated the application of genetically modified oncolytic adenoviruses (OVs) engineered to express bispecific T-cell engager (BiTE) antibodies. Methods: In particular, we engineered Ad5-delta24 to express an EpCAM-targeting BiTE under the major late promoter, yielding the recombinant virus Ad5D24-Anti-EpCAM-Anti-CD3-scFv (rOAd5-BiTE). Following infection of A549 lung cancer cells, rOAd5-BiTE promoted the expression and secretion of BiTE antibodies targeting EpCAM and CD3. Results: In co-culture experiments, rOAd5-BiTE elicited significant T-cell activation and proliferation, characterized by increased secretion of IFN-γ and IL-2, as well as augmented cytotoxic activity from neighboring bystander cells. Moreover, the combination of rOAd5-BiTE with peripheral blood mononuclear cells (PBMCs) markedly enhanced the antitumor activity against A549 cells. Conclusion: The results indicate that equipping OVs with BiTE molecules may address critical challenges in virotherapy by enhancing and redirecting T-cell activity within the tumor microenvironment. This strategy offers a promising avenue for developing targeted immunovirotherapy approaches for the treatment of solid tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.